Elicio Therapeutics, Inc. financial data

Symbol
ELTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
451 D Street, 5 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Angion Biomedica Corp. (to 5/30/2023)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 212 % -36.6%
Debt-to-equity -494 % -514%
Return On Equity 767 % +236%
Return On Assets -194 % -89.9%
Operating Margin -2.61K % -2183%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16M shares +55.9%
Common Stock, Shares, Outstanding 11M shares +14.8%
Entity Public Float 33.2M USD -29.5%
Common Stock, Value, Issued 110K USD +14.6%
Weighted Average Number of Shares Outstanding, Basic 12.2M shares +141%
Weighted Average Number of Shares Outstanding, Diluted 12.2M shares +141%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 653K USD -97.8%
Research and Development Expense 33.7M USD +41.1%
General and Administrative Expense 11.3M USD -4.76%
Costs and Expenses 45M USD +25.9%
Operating Income (Loss) -45M USD -25.9%
Nonoperating Income (Expense) -6.91M USD -1357%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -51.9M USD -47.5%
Earnings Per Share, Basic -4.25 USD/shares +38.9%
Earnings Per Share, Diluted -4.25 USD/shares +38.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.6M USD +36.6%
Other Assets, Current 405K USD -12%
Assets, Current 20.7M USD +26.6%
Property, Plant and Equipment, Net 483K USD -32.6%
Operating Lease, Right-of-Use Asset 5.71M USD -13.1%
Other Assets, Noncurrent 864K USD +1008%
Assets 28.2M USD +3.8%
Accounts Payable, Current 1.04M USD -76.2%
Employee-related Liabilities, Current 2.31M USD +25%
Accrued Liabilities, Current 8.42M USD +124%
Contract with Customer, Liability, Current 1.17M USD +68.4%
Liabilities, Current 11.5M USD +18.1%
Operating Lease, Liability, Noncurrent 5.11M USD -15%
Liabilities 39.5M USD +150%
Accumulated Other Comprehensive Income (Loss), Net of Tax -175K USD +11.2%
Retained Earnings (Accumulated Deficit) -194M USD -36.5%
Stockholders' Equity Attributable to Parent -11.3M USD -199%
Liabilities and Equity 28.2M USD +3.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1M USD -48.9%
Net Cash Provided by (Used in) Financing Activities 11M USD +9.8%
Net Cash Provided by (Used in) Investing Activities 3K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 11M shares +14.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD -158%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.5M USD +36.3%
Deferred Tax Assets, Valuation Allowance 100M USD +11.1%
Operating Lease, Liability 6.01M USD -13.2%
Depreciation 0 USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -51.9M USD -46.6%
Lessee, Operating Lease, Liability, to be Paid 7.39M USD -16.2%
Property, Plant and Equipment, Gross 2.04M USD +4.47%
Operating Lease, Liability, Current 901K USD -0.99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD +2.44%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.35M USD -5.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.38M USD -27.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 64.6M USD +6.51%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.1M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +2.95%
Operating Lease, Payments 379K USD +21.5%
Additional Paid in Capital 183M USD +19%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.45M USD +23.2%
Interest Expense 753K USD -89.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%